Compound brief
Evidence brief. Not treatment advice or a safety clearance. Last evidence update: September 2026.
A very small acidic tetrapeptide. Telomere and pineal claims circulate far ahead of extracted human trials in this sheet.
Four residues are not a telomerase drug because a forum says so.
Telomerase and pineal melatonin are the two stories attached to Ala-Glu-Asp-Gly in forum and preclinical chatter. Neither is an extracted clinical pathway in this seed.
The peptide is acidic and short. Proteolysis and actual target engagement are unknown here.
Forum themes are unverified. They do not outrank a study, and they are not a dose.
Telomere claims · unverified
Forums state telomere lengthening as if it were a routine lab result. The tetrapeptide chemistry in this seed does not carry a clinical telomerase trial.
Theme summarized from public discussion. Not a quoted post, not a trial, and not a dose.